Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics

[1]  R. Cavalli,et al.  Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. , 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  M. Miura,et al.  An update on the clinical pharmacokinetics of fexofenadine enantiomers , 2018, Expert opinion on drug metabolism & toxicology.

[3]  G. Koren,et al.  The role of the placenta in drug transport and fetal drug exposure , 2018, Expert review of clinical pharmacology.

[4]  T. Field.  Prenatal anxiety effects: A review. , 2017, Infant behavior & development.

[5]  E. Rytting,et al.  Placental control of drug delivery☆ , 2017, Advanced drug delivery reviews.

[6]  Fei Li,et al.  Influence of P‐glycoprotein on the disposition of fexofenadine and its enantiomers , 2017, The Journal of pharmacy and pharmacology.

[7]  R. Cavalli,et al.  Analysis of Fluoxetine and Norfluoxetine Enantiomers in Human Plasma and Amniotic Fluid by LC-MS / MS and Its Application to Clinical Pharmacokinetics in Pregnant Women , 2017 .

[8]  Anand A. Joshi,et al.  Placental ABC Transporters: Biological Impact and Pharmaceutical Significance , 2016, Pharmaceutical Research.

[9]  M. Hebert,et al.  Pregnancy‐related pharmacokinetic changes , 2016, Clinical pharmacology and therapeutics.

[10]  C. Chambers,et al.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence , 2016, CNS Drugs.

[11]  N. Yasui-Furukori,et al.  The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. , 2015, Drug metabolism and pharmacokinetics.

[12]  N. Yasui-Furukori,et al.  Effects of multiple‐dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers , 2015, Journal of Clinical Pharmacy and Therapeutics.

[13]  J. Fink-Gremmels,et al.  Inhibition of P-glycoprotein by psychotherapeutic drugs in a canine cell model. , 2014, Journal of veterinary pharmacology and therapeutics.

[14]  H. Kusuhara,et al.  Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers , 2014, European Journal of Clinical Pharmacology.

[15]  H. Tada,et al.  Enantioselective uptake of fexofenadine by Caco‐2 cells as model intestinal epithelial cells , 2013, The Journal of pharmacy and pharmacology.

[16]  H. Kusuhara,et al.  Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects , 2013, Drug Metabolism and Disposition.

[17]  Ulf Norinder,et al.  Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions , 2012, Journal of medicinal chemistry.

[18]  N. Yasui-Furukori,et al.  Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. , 2012, British journal of clinical pharmacology.

[19]  E. Gundogdu,et al.  Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies , 2011, International journal of nanomedicine.

[20]  N. Yasui-Furukori,et al.  Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  M. Miura,et al.  Clinical pharmacokinetics of fexofenadine enantiomers , 2010, Expert opinion on drug metabolism & toxicology.

[22]  M. Miura,et al.  Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. , 2009, British journal of clinical pharmacology.

[23]  D. Peer,et al.  Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. , 2009, Cancer letters.

[24]  B. Kirby,et al.  Effects of Pregnancy on CYP3A and P‐glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study , 2008, Clinical pharmacology and therapeutics.

[25]  M. Miura,et al.  The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. , 2008, British journal of clinical pharmacology.

[26]  W. Ray,et al.  Increasing use of antidepressants in pregnancy. , 2007, American journal of obstetrics and gynecology.

[27]  M. Miura,et al.  Pharmacokinetics of fexofenadine enantiomers in healthy subjects. , 2007, Chirality.

[28]  Gerald Gartlehner,et al.  Perinatal Depression: A Systematic Review of Prevalence and Incidence , 2005, Obstetrics and gynecology.

[29]  J. Hitti,et al.  P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[30]  H. Kusuhara,et al.  P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION , 2005, Drug Metabolism and Disposition.

[31]  N. Yasui-Furukori,et al.  Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[32]  D. Peer,et al.  Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models , 2004, Cancer Research.

[33]  C. DeVane.  Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors , 1999, Cellular and Molecular Neurobiology.

[34]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[35]  M. Owens,et al.  Stereochemistry in Drug Action. , 2003, Primary care companion to the Journal of clinical psychiatry.

[36]  W. Haefeli,et al.  Inhibition of P-Glycoprotein by Newer Antidepressants , 2003, Journal of Pharmacology and Experimental Therapeutics.

[37]  C. DeVane,et al.  Great Expectations in Stereochemistry: Focus on Antidepressants , 2002, CNS Spectrums.

[38]  S. Pallanti,et al.  Shame and Psychopathology , 2000, CNS Spectrums.

[39]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[40]  D. J. Pack,et al.  Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16 455) and its enantiomers in healthy male volunteers , 1998, Biopharmaceutics & drug disposition.

[41]  R. Fuller,et al.  Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo , 1992, Neuropharmacology.

[42]  D. Wong,et al.  Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. , 1990, Acta pharmaceutica Nordica.